JP2012518656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012518656A5 JP2012518656A5 JP2011551299A JP2011551299A JP2012518656A5 JP 2012518656 A5 JP2012518656 A5 JP 2012518656A5 JP 2011551299 A JP2011551299 A JP 2011551299A JP 2011551299 A JP2011551299 A JP 2011551299A JP 2012518656 A5 JP2012518656 A5 JP 2012518656A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- coating
- controlled release
- core
- anticholinergic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 53
- 238000000576 coating method Methods 0.000 claims 24
- 239000011248 coating agent Substances 0.000 claims 21
- 238000013270 controlled release Methods 0.000 claims 17
- 239000002245 particle Substances 0.000 claims 15
- 239000000812 cholinergic antagonist Substances 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 11
- 229920003176 water-insoluble polymer Polymers 0.000 claims 11
- -1 biveridene Chemical compound 0.000 claims 10
- 229920000642 polymer Polymers 0.000 claims 10
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 8
- 238000009472 formulation Methods 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 6
- 230000001078 anti-cholinergic effect Effects 0.000 claims 5
- 150000001720 carbohydrates Chemical class 0.000 claims 5
- CURUTKGFNZGFSE-UHFFFAOYSA-N dicyclomine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 claims 5
- 229960002777 dicycloverine Drugs 0.000 claims 5
- 239000008187 granular material Substances 0.000 claims 5
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000000120 Artificial Saliva Substances 0.000 claims 3
- 239000001856 Ethyl cellulose Substances 0.000 claims 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 3
- 239000007884 disintegrant Substances 0.000 claims 3
- 229920001249 ethyl cellulose Polymers 0.000 claims 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims 3
- 239000004014 plasticizer Substances 0.000 claims 3
- 210000003296 saliva Anatomy 0.000 claims 3
- 150000005846 sugar alcohols Chemical class 0.000 claims 3
- WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 claims 2
- GFRUPHOKLBPHTQ-UHFFFAOYSA-N 2-(2-cyclohexyl-2-hydroxy-1-oxo-2-phenylethoxy)ethyl-diethyl-methylammonium Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC[N+](C)(CC)CC)C1CCCCC1 GFRUPHOKLBPHTQ-UHFFFAOYSA-N 0.000 claims 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims 2
- YXSLJKQTIDHPOT-UHFFFAOYSA-N Atracurium Dibesylate Chemical compound C1=C(OC)C(OC)=CC=C1CC1[N+](CCC(=O)OCCCCCOC(=O)CC[N+]2(C)C(C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 YXSLJKQTIDHPOT-UHFFFAOYSA-N 0.000 claims 2
- 229930003347 Atropine Natural products 0.000 claims 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 claims 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 2
- WMSYWJSZGVOIJW-ONUALHDOSA-L Mivacurium chloride Chemical compound [Cl-].[Cl-].C([C@@H]1C2=CC(OC)=C(OC)C=C2CC[N+]1(C)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(CCC=2C=C(C(=CC=2[C@H]1CC=1C=C(OC)C(OC)=C(OC)C=1)OC)OC)C)C1=CC(OC)=C(OC)C(OC)=C1 WMSYWJSZGVOIJW-ONUALHDOSA-L 0.000 claims 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims 2
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 claims 2
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 claims 2
- 229960001862 atracurium Drugs 0.000 claims 2
- 229960000396 atropine Drugs 0.000 claims 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical group O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims 2
- 229960001081 benzatropine Drugs 0.000 claims 2
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 claims 2
- HOZOZZFCZRXYEK-GSWUYBTGSA-M butylscopolamine bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-GSWUYBTGSA-M 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 2
- 229960000358 cisatracurium Drugs 0.000 claims 2
- YXSLJKQTIDHPOT-LJCJQEJUSA-N cisatracurium Chemical compound C1=C(OC)C(OC)=CC=C1C[C@H]1[N@+](CCC(=O)OCCCCCOC(=O)CC[N@+]2(C)[C@@H](C3=CC(OC)=C(OC)C=C3CC2)CC=2C=C(OC)C(OC)=CC=2)(C)CCC2=CC(OC)=C(OC)C=C21 YXSLJKQTIDHPOT-LJCJQEJUSA-N 0.000 claims 2
- 229920001577 copolymer Polymers 0.000 claims 2
- 239000007771 core particle Substances 0.000 claims 2
- QTBCATBNRIYMPB-UHFFFAOYSA-N cyclohexyl-hydroxy-phenyl-(3-piperidin-1-ylpropyl)silane Chemical compound C1CCCCC1[Si](C=1C=CC=CC=1)(O)CCCN1CCCCC1 QTBCATBNRIYMPB-UHFFFAOYSA-N 0.000 claims 2
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 claims 2
- 229960002677 darifenacin Drugs 0.000 claims 2
- 229950000405 decamethonium Drugs 0.000 claims 2
- LQQIVYSCPWCSSD-HSZRJFAPSA-N dexetimide Chemical compound O=C1NC(=O)CC[C@@]1(C=1C=CC=CC=1)C1CCN(CC=2C=CC=CC=2)CC1 LQQIVYSCPWCSSD-HSZRJFAPSA-N 0.000 claims 2
- 229960001908 dexetimide Drugs 0.000 claims 2
- JEJBJBKVPOWOQK-UHFFFAOYSA-N emepronium Chemical compound C=1C=CC=CC=1C(CC(C)[N+](C)(C)CC)C1=CC=CC=C1 JEJBJBKVPOWOQK-UHFFFAOYSA-N 0.000 claims 2
- 229960002236 emepronium Drugs 0.000 claims 2
- 229940015042 glycopyrrolate Drugs 0.000 claims 2
- 229950002932 hexamethonium Drugs 0.000 claims 2
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 claims 2
- 229960002525 mecamylamine Drugs 0.000 claims 2
- 229960002540 mivacurium Drugs 0.000 claims 2
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 claims 2
- 229960003941 orphenadrine Drugs 0.000 claims 2
- 229960005434 oxybutynin Drugs 0.000 claims 2
- 229960002740 oxyphenonium Drugs 0.000 claims 2
- 229960005457 pancuronium Drugs 0.000 claims 2
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 claims 2
- RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 claims 2
- 229960004633 pirenzepine Drugs 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229960005253 procyclidine Drugs 0.000 claims 2
- 229960000697 propantheline Drugs 0.000 claims 2
- 229960001404 quinidine Drugs 0.000 claims 2
- YXRDKMPIGHSVRX-OOJCLDBCSA-N rocuronium Chemical compound N1([C@@H]2[C@@H](O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(CC=C)CCCC2)CCOCC1 YXRDKMPIGHSVRX-OOJCLDBCSA-N 0.000 claims 2
- 229960000491 rocuronium Drugs 0.000 claims 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims 2
- 229960002646 scopolamine Drugs 0.000 claims 2
- 229950009846 scopolamine butylbromide Drugs 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229940032712 succinylcholine Drugs 0.000 claims 2
- AXOIZCJOOAYSMI-UHFFFAOYSA-N succinylcholine Chemical compound C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C AXOIZCJOOAYSMI-UHFFFAOYSA-N 0.000 claims 2
- 229960004045 tolterodine Drugs 0.000 claims 2
- 229960001032 trihexyphenidyl Drugs 0.000 claims 2
- KVXLWKVCHTZKLP-UHFFFAOYSA-N trimethyl(2-phenylmethoxypentyl)azanium Chemical compound CCCC(C[N+](C)(C)C)OCC1=CC=CC=C1 KVXLWKVCHTZKLP-UHFFFAOYSA-N 0.000 claims 2
- HLXQFVXURMXRPU-UHFFFAOYSA-L trimethyl-[10-(trimethylazaniumyl)decyl]azanium;dibromide Chemical compound [Br-].[Br-].C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C HLXQFVXURMXRPU-UHFFFAOYSA-L 0.000 claims 2
- PYIHTIJNCRKDBV-UHFFFAOYSA-L trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCCCCC[N+](C)(C)C PYIHTIJNCRKDBV-UHFFFAOYSA-L 0.000 claims 2
- 229960004791 tropicamide Drugs 0.000 claims 2
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 claims 2
- 229960001844 tubocurarine Drugs 0.000 claims 2
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 claims 2
- 229960003819 vecuronium Drugs 0.000 claims 2
- BGSZAXLLHYERSY-XQIGCQGXSA-N vecuronium Chemical compound N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 BGSZAXLLHYERSY-XQIGCQGXSA-N 0.000 claims 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 102000006835 Lamins Human genes 0.000 claims 1
- 108010047294 Lamins Proteins 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 1
- 229940127450 Opioid Agonists Drugs 0.000 claims 1
- OWWLUIWOFHMHOQ-XGHATYIMSA-N Pipecuronium Chemical compound N1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)N2CC[N+](C)(C)CC2)CC[N+](C)(C)CC1 OWWLUIWOFHMHOQ-XGHATYIMSA-N 0.000 claims 1
- 229920001800 Shellac Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000001088 anti-asthma Effects 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 230000000648 anti-parkinson Effects 0.000 claims 1
- 230000003356 anti-rheumatic effect Effects 0.000 claims 1
- 230000002921 anti-spasmodic effect Effects 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 229940125692 cardiovascular agent Drugs 0.000 claims 1
- 239000002327 cardiovascular agent Substances 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004581 coalescence Methods 0.000 claims 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 230000009089 cytolysis Effects 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 239000004083 gastrointestinal agent Substances 0.000 claims 1
- 229940127227 gastrointestinal drug Drugs 0.000 claims 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 1
- 210000005053 lamin Anatomy 0.000 claims 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 239000003887 narcotic antagonist Substances 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 229940066405 octylonium Drugs 0.000 claims 1
- NQHNLNLJPDMBFN-UHFFFAOYSA-O otilonium bromide Chemical compound CCCCCCCCOC1=CC=CC=C1C(=O)NC1=CC=C(C(=O)OCC[N+](C)(CC)CC)C=C1 NQHNLNLJPDMBFN-UHFFFAOYSA-O 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 229960001260 pipecuronium Drugs 0.000 claims 1
- 229920005596 polymer binder Polymers 0.000 claims 1
- 239000002491 polymer binding agent Substances 0.000 claims 1
- 229920002689 polyvinyl acetate Polymers 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims 1
- 239000004208 shellac Substances 0.000 claims 1
- 229940113147 shellac Drugs 0.000 claims 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims 1
- 235000013874 shellac Nutrition 0.000 claims 1
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 claims 1
- 229940023144 sodium glycolate Drugs 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 229940120904 succinylcholine chloride Drugs 0.000 claims 1
- YOEWQQVKRJEPAE-UHFFFAOYSA-L succinylcholine chloride (anhydrous) Chemical compound [Cl-].[Cl-].C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C YOEWQQVKRJEPAE-UHFFFAOYSA-L 0.000 claims 1
- CHQOEHPMXSHGCL-UHFFFAOYSA-N trimethaphan Chemical compound C12C[S+]3CCCC3C2N(CC=2C=CC=CC=2)C(=O)N1CC1=CC=CC=C1 CHQOEHPMXSHGCL-UHFFFAOYSA-N 0.000 claims 1
- 229940035742 trimethaphan Drugs 0.000 claims 1
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15450409P | 2009-02-23 | 2009-02-23 | |
| US61/154,504 | 2009-02-23 | ||
| PCT/US2010/025083 WO2010096820A1 (en) | 2009-02-23 | 2010-02-23 | Controlled release compositions comprising anti-cholinergic drugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015087928A Division JP2015155441A (ja) | 2009-02-23 | 2015-04-22 | 抗コリン薬を具える放出制御組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012518656A JP2012518656A (ja) | 2012-08-16 |
| JP2012518656A5 true JP2012518656A5 (enExample) | 2013-04-11 |
| JP5878022B2 JP5878022B2 (ja) | 2016-03-08 |
Family
ID=42634253
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011551299A Expired - Fee Related JP5878022B2 (ja) | 2009-02-23 | 2010-02-23 | 抗コリン薬を具える放出制御組成物 |
| JP2015087928A Pending JP2015155441A (ja) | 2009-02-23 | 2015-04-22 | 抗コリン薬を具える放出制御組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015087928A Pending JP2015155441A (ja) | 2009-02-23 | 2015-04-22 | 抗コリン薬を具える放出制御組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110311626A1 (enExample) |
| EP (1) | EP2398469A4 (enExample) |
| JP (2) | JP5878022B2 (enExample) |
| CA (1) | CA2753416A1 (enExample) |
| WO (1) | WO2010096820A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2398469A4 (en) * | 2009-02-23 | 2013-09-04 | Aptalis Pharmatech Inc | ANTICHOLINERGIC CONTAINING DELAYED RELEASE COMPOSITION |
| BR112012012999A2 (pt) | 2009-11-30 | 2019-04-02 | Aptalis Pharmatech Inc | Composição farmacêutica, e composição de tablete de desintegração oral (odt) outablete de dispersão rápida (rdt) |
| GR1007628B (el) * | 2011-07-27 | 2012-06-29 | Φαρματεν Αβεε, | Φαρμακευτικο σκευασμα περιεχον εναν αντιμουσκαρινικο παραγοντα και μεθοδος για την παρασκευη αυτου |
| US20150086626A1 (en) * | 2012-04-17 | 2015-03-26 | Mylan, Inc | Stable dosage forms of skeletal muscle relaxants with extended release coating |
| AU2014306759B2 (en) | 2013-08-12 | 2018-04-26 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015056851A1 (ko) * | 2013-10-18 | 2015-04-23 | 주식회사 한독 | 아리피프라졸 함유 구강 붕해 정제 및 이의 제조 방법 |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| ES2809458T3 (es) | 2014-07-17 | 2021-03-04 | Pharmaceutical Manufacturing Res Services Inc | Forma de dosificación llena de líquido, disuasoria del abuso y de liberación inmediata |
| WO2016064873A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| KR20180125573A (ko) * | 2016-03-31 | 2018-11-23 | 인터셉트 파마슈티컬즈, 인크. | 유효 성분의 화학적 안정성이 뛰어난 필름 코팅정 |
| WO2019157066A1 (en) * | 2018-02-06 | 2019-08-15 | Robert Niichel | A multiparticulate including pharmaceutical or probiotic active ingredients |
| JP7273976B2 (ja) | 2018-09-21 | 2023-05-15 | アムニール コンプレックス プロダクツ リサーチ エルエルシー | トリヘキシフェニジルを含む徐放性組成物 |
| US11154505B1 (en) | 2021-02-03 | 2021-10-26 | Kashiv Specialty Pharmaceuticals, Llc | Extended release compositions comprising trihexyphenidyl |
| CN113244238B (zh) * | 2021-06-16 | 2022-05-20 | 北京斯利安药业有限公司 | 含盐酸苯海索和叶酸的口崩片及其制备方法 |
| US11648207B1 (en) * | 2021-12-15 | 2023-05-16 | Intas Pharmaceuticals Ltd. | Extended release pharmaceutical composition of Clozapine |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE133331T1 (de) * | 1991-11-13 | 1996-02-15 | Glaxo Canada | Vorrichtung zur kontrollierten wirkstoffreigabe |
| ES2245320T3 (es) * | 1999-11-11 | 2006-01-01 | Pfizer Health Ab | Formulacion farmaceutica que contiene tolterodina y su uso. |
| MXPA03009588A (es) * | 2001-04-18 | 2004-12-06 | Nostrum Pharmaceuticals Inc | Un recubrimiento novedoso para una composicion farmaceutica de liberacion sostenida. |
| US6500454B1 (en) * | 2001-10-04 | 2002-12-31 | Eurand Pharmaceuticals Ltd. | Timed, sustained release systems for propranolol |
| US20030091630A1 (en) * | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| SE0203065D0 (sv) * | 2002-10-16 | 2002-10-16 | Diabact Ab | Gastric acid secretion inhibiting composition |
| US20060024361A1 (en) * | 2004-07-28 | 2006-02-02 | Isa Odidi | Disintegrant assisted controlled release technology |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| KR101468053B1 (ko) * | 2006-08-31 | 2014-12-02 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 약물의 고용체를 포함하는 약물 전달 시스템 |
| WO2009006413A1 (en) * | 2007-06-30 | 2009-01-08 | Auspex Pharmaceuticals, Inc. | Substituted pyrrolidines |
| US8486452B2 (en) * | 2007-07-20 | 2013-07-16 | Mylan Pharmaceuticals Inc. | Stabilized tolterodine tartrate formulations |
| EP2175843B1 (en) * | 2007-08-08 | 2014-10-08 | Inventia Healthcare Private Limited | Extended release compositions comprising tolterodine |
| EP2398469A4 (en) * | 2009-02-23 | 2013-09-04 | Aptalis Pharmatech Inc | ANTICHOLINERGIC CONTAINING DELAYED RELEASE COMPOSITION |
-
2010
- 2010-02-23 EP EP10744475.4A patent/EP2398469A4/en not_active Withdrawn
- 2010-02-23 WO PCT/US2010/025083 patent/WO2010096820A1/en not_active Ceased
- 2010-02-23 US US13/202,957 patent/US20110311626A1/en not_active Abandoned
- 2010-02-23 CA CA2753416A patent/CA2753416A1/en not_active Abandoned
- 2010-02-23 JP JP2011551299A patent/JP5878022B2/ja not_active Expired - Fee Related
-
2015
- 2015-04-22 JP JP2015087928A patent/JP2015155441A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012518656A5 (enExample) | ||
| JP5878022B2 (ja) | 抗コリン薬を具える放出制御組成物 | |
| Dashevsky et al. | Compression of pellets coated with various aqueous polymer dispersions | |
| JP2020059755A5 (enExample) | ||
| JP2008540419A5 (enExample) | ||
| JP2017019858A5 (enExample) | ||
| JP2012153724A5 (enExample) | ||
| US9579288B2 (en) | Tesofensine and beta blocker combination formulations | |
| CA2798700A1 (en) | Alcohol-resistant formulations | |
| CN106389381A (zh) | 金刚烷胺组合物及其使用方法 | |
| JP2017528521A (ja) | アリモクロモル製剤 | |
| KR20150043497A (ko) | 약제 함유 할로우 입자 | |
| US20090311317A1 (en) | Modified release tolterodine formulations | |
| JPH08109126A (ja) | 耐衝撃性腸溶性顆粒剤およびこれを含有する錠剤 | |
| CN102091053B (zh) | 一种颗粒组合控释片 | |
| CA2645940A1 (en) | Controlled release formulation of tolterodine | |
| CA2798702A1 (en) | Alcoholresistant metoprolol-containing extended-release oral dosage forms | |
| US20070082051A1 (en) | Modified Release Formulations of Antihypertensive Drugs | |
| JP2022514040A (ja) | 耐酸性に優れたタムスロシン塩酸塩含有医薬組成物及びその製造方法 | |
| CN110507627A (zh) | 一种布地奈德的口服控释药物组合物 | |
| JP3870470B2 (ja) | マルチプルユニットタイプ徐放性錠剤 | |
| CA2798701A1 (en) | Alcohol-resistant extended release dosage forms comprising venlafaxine | |
| AU2006274565B2 (en) | Novel controlled release compositions of selective serotonin reuptake inhibitors | |
| CN109260168B (zh) | 一种盐酸可乐定缓释片 | |
| JPWO2022181625A5 (enExample) |